Immatics N.V. (IMTX) carries a Roarable Rating of D+ (Sell) with 52/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 7/9
SEC XBRL Trailing 12 Months: 0.8% FCF Margin ($30.6M FCF) & 52% Gross Margin
Put hedging (50% put share) caps near-term gamma upside (-12 pts vs max)
While IMTX currently carries a cautious 52/100 (D+) rating due to Whale & Options Positioning (8/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
Established market leader in Health Care with deep daily trading liquidity.
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($8.25) and Max Pain ($7.68) forces dealer call-delta covering toward $13.03.
Forensic Repair Trigger: Halting share dilution (Disciplined Float (-0.40% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
Immatics N.V. (IMTX) slipped -0.54% to $7.31, trading at 11% of its 52-week range ($6.65 – $12.41). Stretched risk/reward at current multiples (steady margins) under elevated 10-year interest-rate pressure.
What the new PRAME data means for Immatics stock Fresh clinical results for Immatics (NasdaqCM:IMTX) are in focus after updated Phase 1b IMA402 and Phase 1 IMA203CD8 data in PRAME expressing solid tumors were shared at t
Bristol Myers (BMY) delivered earnings and revenue surprises of +11.57% and +4.07%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?
Immatics has logged a sizeable share price decline over the past few years, even as fresh clinical data has put its PRAME cancer therapies in the spotlight. That raises a straightforward question for you as an investor:
IMA402 PRAME bispecific continues to demonstrate encouraging anti-tumor activity in multiple indications, alongside a favorable safety profileIMA402 achieved a cORR of 32%, 12.5 months median DOR and a 1-year OS rate of
Immatics released updated Phase 1 data at the 2026 ESMO meeting showing that IMA402 and IMA203CD8 delivered objective responses and disease control in heavily pretreated patients with PRAME-expressing solid tumors, along
IMA402 PRAME bispecific continues to demonstrate encouraging anti-tumor activity in multiple indications, alongside a favorable safety profileIMA402 achieved a cORR of 32%, 12.5 months median DOR and a 1-year OS rate of
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
No active Ellis Vennor swing setup published on IMTX today. View full Setup Ledger →
No direct multi-tier Butterfly edges indexed yet for IMTX. Explore sector supply chains on /butterfly.
Across 1016 tracked Health Care securities in the Roarable RQD universe, Immatics N.V. (IMTX) ranks #319 by composite RQD confidence (52/100, grade D+) and #352 by equity capitalization ($1.09B). Within this direct 5-issuer industry benchmark cohort, IMTX leads on earnings valuation at N/A trailing P/E, while INBX leads on capital efficiency and profitability with -35.0% ROIC and — gross margin. ODTX currently holds the highest overall quantitative score in the immediate peer group at 59/100 (C-) compared with IMTX at 52/100 (D+).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| IMTX
ACTIVE
Immatics N.V. | D+ | 52/100 | — | — | — | -0.54% | $1.09B | Benchmark Subject |
| INBX Inhibrx Biosciences Inc. | E | 31/100 | — | — | -35.0% | +0.49% | $1.08B | /inbx-vs-imtx → |
| CGEM Cullinan Therapeutics Inc. | D- | 36/100 | — | — | -35.0% | -0.71% | $994.3M | /cgem-vs-imtx → |
| VOR Vor Biopharma Inc. | D- | 37/100 | — | — | -35.0% | +1.26% | $1.24B | /vor-vs-imtx → |
| ODTX Odyssey Therapeutics Inc. | C- | 59/100 | — | — | — | +1.48% | $953.0M | /odtx-vs-imtx → |
Immatics N.V. (IMTX) operates in Biotechnology: Biological Products (No Diagnostic Substances) (Health Care) with an equity capitalization of $1.09B, trailing P/E of N/A, forward P/E of N/A, and EV/EBITDA of N/A. Operating profitability registers a gross margin of —, operating margin of —, net profit margin of —, ROIC of —, and free cash flow yield of —, alongside an Altman Z-Score of N/A and Piotroski F-Score of N/A.
As of 2026-11-01, Immatics N.V. (NASDAQ: IMTX) is rated D+ (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 52/100 at a spot price of $7.31 (-0.54% 1D, market cap $1.09B). Pillar breakdown: Fundamental Cash Engine 12/20, Institutional 13F & Options Flow 8/20, Executive Insider Alignment 13/20, FRED Macro Regime Fit 10/20, and SEC Balance-Sheet Forensics 9/20. Across 1016 tracked Health Care issuers, IMTX ranks #319 in composite RQD confidence.
Within the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)), IMTX carries a Roarable D+ (52/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of —. By comparison, INBX (Inhibrx Biosciences Inc.) holds a E grade (31/100 RQD, P/E N/A, ROIC -35.0%, cap $1.08B) and CGEM (Cullinan Therapeutics Inc.) posts a D- grade (36/100 RQD, P/E N/A, ROIC -35.0%, cap $994.3M). Among the 5-stock peer group, IMTX leads on earnings multiple (N/A) while INBX leads on capital efficiency (-35.0% ROIC).
For Immatics N.V. (IMTX), key quantitative strengths include Established market leader in Health Care with deep daily trading liquidity. and sector rank #319 in Health Care, while primary risk factors center on Company executives have done more routine share selling than personal cash buying lately. and Sensitive to high interest rates and tighter Federal Reserve market liquidity.. Institutional options positioning shows a 50% call / 50% put premium split.
IMTX last traded at $7.31 (-0.54% on volume of 1,178,962 shares), positioning the stock -11.39% below its 50-day simple moving average ($8.25) and -23.77% below its 200-day simple moving average ($9.59). Across its 52-week range of $6.65 to $12.41, IMTX sits at the 11.5% percentile with a 14-day RSI of 41.6 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($6.40 to $8.22).
Why IMTX Stock slipped -0.54% Today — RQD Quant Desk Flash. Stretched risk/reward at current multiples (steady margins) under elevated 10-year interest-rate pressure.
To protect compute speed and zero-delay Cboe BZX data quality for active members, our current $9.95/month Roarable Pro cohort is 100% full. Join the priority waiting list below and we will notify you the moment the next batch of Pro accounts opens (and lock in your $9.95/mo rate).
Link your personal ChatGPT, Claude Desktop, or Cursor via Roarable's Model Context Protocol (`mcp.roarable.com`) to query all 5,289 stocks, inspect Butterfly supply chains, and trade your `$100K Arena` account.
Interrogate SEC 10-K/10-Q filings on demand and ask custom ticker, valuation, or short-thesis questions directly to any of our 8 specialized AI Quant Analysts.
Command our AI agents to sort and sift 5,289 stocks by custom formulas, follow multi-indicator technical & cash-flow setups, and send you instant Email/SMS breakout & downgrade alerts.
Unlock sub-second Cboe BZX streaming quotes, pre-market/after-hours delta scanners, instant SEC Form 4 insider cluster alerts, and unlimited portfolio stress-testing.
All 8 Roarable Analysts (Mara Quenwick, Devon Kess, Gideon Vane, Eliott Vance, Sorel Thorne, Corin Hale, Tessa Rane, and Felix Orven) are proprietary AI Quant Analysts and automated algorithmic specialists — not human financial advisors, fiduciaries, or registered broker-dealers. While one-to-many daily stock ratings and briefings are free, custom 1-on-1 Q&A, custom AI sifting/indicator alert agents, and personal ChatGPT/Claude MCP connections consume dedicated per-user compute and require a $9.95/month Roarable Pro membership. All AI outputs are for educational and research purposes only and never constitute individualized investment advice.
Enter your Google email below for instant 1-step account activation, daily A–E stock rating alerts, and immediate access to your $100,000.00 Paper Trading Arena account.